☰

Nidal H. AL-Huniti, Ph.D. - Publications

Affiliations: 
2005 University of Iowa, Iowa City, IA 
Area:
Pharmacy
Tree Info Grants Similar researchers PubMed Report error

9/61 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Al-Huniti N, Chapel S, Xu H, Bui KH, Sostek M. Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients. British Journal of Clinical Pharmacology. 81: 89-100. PMID 26317320 DOI: 10.1111/Bcp.12756  0.601
2007 Widness JA, Schmidt RL, Hohl RJ, Goldman FD, Al-Huniti NH, Freise KJ, Veng-Pedersen P. Change in erythropoietin pharmacokinetics following hematopoietic transplantation Clinical Pharmacology and Therapeutics. 81: 873-879. PMID 17429351 DOI: 10.1038/Sj.Clpt.6100165  0.639
2007 Gupta N, Al-Huniti NH, Veng-Pedersen P. Individualized pharmacokinetic risk assessment for development of diabetes in high risk population. Diabetes Research and Clinical Practice. 78: 93-101. PMID 17368857 DOI: 10.1016/J.Diabres.2007.02.013  0.516
2005 Al-Huniti NH, Widness JA, Schmidt RL, Veng-Pedersen P. Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis. Journal of Pharmacokinetics and Pharmacodynamics. 32: 359-76. PMID 16284920 DOI: 10.1007/S10928-005-0009-3  0.543
2004 Al-Huniti NH, Widness JA, Schmidt RL, Veng-Pedersen P. Erythropoietin production rate in phlebotomy-induced acute anemia. Biopharmaceutics & Drug Disposition. 25: 389-97. PMID 15529399 DOI: 10.1002/Bdd.424  0.527
2004 Veng-Pedersen P, Chapel S, Al-Huniti NH, Schimdt RL, Sedars EM, Hohl RJ, Widness JA. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phylebotomy-induced anemia and bone marrow ablation Biopharmaceutics and Drug Disposition. 25: 149-156. PMID 15108217 DOI: 10.1002/bdd.395  0.662
2004 Al-Huniti NH, Widness JA, Schmidt RL, Veng-Pedersen P. Pharmacokinetic/pharmacodynamic analysis of paradoxal regulation of erythropoietin production in acute anemia. The Journal of Pharmacology and Experimental Therapeutics. 310: 202-8. PMID 14988424 DOI: 10.1124/Jpet.104.066027  0.594
2003 Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, Widness JA. A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep Journal of Pharmacology and Experimental Therapeutics. 306: 532-537. PMID 12750427 DOI: 10.1124/Jpet.103.052431  0.645
2002 Veng-Pederson P, Chapel S, Schmidt PRL, Al-Huniti NH, Cook RT, Widness JA. An integrated pharmacodynamic analysis of erythropoietin, reticulocyte, and hemoglobin responses in acute anemia Pharmaceutical Research. 19: 1630-1635. PMID 12458668 DOI: 10.1023/A:1020797110836  0.612
Low-probability matches (unlikely to be authored by this person)
2015 Zhou D, Bui KH, Li J, Al-Huniti N. Population pharmacokinetic modeling of quetiapine after administration of SEROQUEL and SEROQUEL XR formulations to western and Chinese patients with schizophrenia, schizoaffective disorder or bipolar disorder. Journal of Clinical Pharmacology. PMID 25975812 DOI: 10.1002/Jcph.544  0.201
2021 Pu X, Sale M, Yang F, Zhang Y, Davis JD, Al-Huniti N. Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemia. Cpt: Pharmacometrics & Systems Pharmacology. PMID 34585515 DOI: 10.1002/psp4.12711  0.198
2016 Bui K, Zhou D, Xu H, Floettmann E, Al-Huniti N. Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist. Clinical Pharmacokinetics. PMID 28035588 DOI: 10.1007/S40262-016-0479-Z  0.191
2017 Zhou W, Li J, Birmingham B, Xu H, Lillieborg S, Zhou D, Al-Huniti N. Population Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With Migraine. Journal of Clinical Pharmacology. PMID 28581633 DOI: 10.1002/jcph.935  0.177
2019 Zhou L, Sharma P, Yeo KR, Higashimori M, Xu H, Al-Huniti N, Zhou D. Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 105061. PMID 31479720 DOI: 10.1016/j.ejps.2019.105061  0.176
2018 Tong X, Zhou D, Savage A, Mullen JA, Li Y, Taylor W, Li J, Al-Huniti N, Xu H. Population Pharmacokinetic Modeling With Enterohepatic Circulation for AZD3241 in Healthy Subjects and Patients With Multiple System Atrophy. Journal of Clinical Pharmacology. PMID 29873817 DOI: 10.1002/jcph.1134  0.175
2017 Al-Huniti N, Xu H, Zhou D, Aksenov S, Fox R, Bui KH. Population Exposure-Response Modeling Supported Selection of Naloxegol Doses in Phase 3 Studies in Patients with Opioid Induced Constipation. Cpt: Pharmacometrics & Systems Pharmacology. PMID 28782266 DOI: 10.1002/psp4.12229  0.173
2018 Edlund H, Lee SK, Andrew MA, Slatter JG, Aksenov S, Al-Huniti N. Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies. Clinical Pharmacokinetics. PMID 30556110 DOI: 10.1007/s40262-018-0725-7  0.171
2016 Xu H, Zhou W, Zhou D, Li J, Al-Huniti N. Evaluation of Aztreonam Dosing Regimens in Patients with Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis. Journal of Clinical Pharmacology. PMID 27530649 DOI: 10.1002/jcph.810  0.17
2019 Li J, Das S, Zhou D, Al-Huniti N. Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil. Clinical Pharmacology in Drug Development. PMID 31044546 DOI: 10.1002/cpdd.673  0.168
2015 Xu H, Li J, Webber L, Kakkar R, Chen Y, Al-Huniti N. Population Pharmacokinetic and Pharmacodynamic Modeling of AZD4901 and Simulation to Support Dose Selection for the Phase IIa Study. Journal of Clinical Pharmacology. PMID 26626581 DOI: 10.1002/jcph.680  0.165
2019 Zhou L, Tong X, Sharma P, Xu H, Al-Huniti N, Zhou D. Physiologically-Based Pharmacokinetic Modelling to Predict Exposure Differences in Healthy Volunteers and Subjects with Renal Impairment: Ceftazidime Case Study. Basic & Clinical Pharmacology & Toxicology. PMID 30739396 DOI: 10.1111/bcpt.13209  0.165
2015 Bui K, Zhou D, Sostek M, She F, Al-Huniti N. Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol. Journal of Clinical Pharmacology. PMID 26678015 DOI: 10.1002/Jcph.693  0.163
2017 Chen Y, Zhou D, Tang W, Zhou W, Al-Huniti N, Masson E. Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. Journal of Clinical Pharmacology. PMID 29193123 DOI: 10.1002/jcph.1036  0.162
2015 Dykstra K, Mehrotra N, Tornøe CW, Kastrissios H, Patel B, Al-Huniti N, Jadhav P, Wang Y, Byon W. Reporting guidelines for population pharmacokinetic analyses. Journal of Clinical Pharmacology. 55: 875-87. PMID 26148467 DOI: 10.1002/Jcph.532  0.16
2017 Zhou W, Humphries H, Neuhoff S, Gardner I, Masson E, Al-Huniti N, Zhou D. Development of a physiologically based pharmacokinetic model to predict the effects of Flavin-Containing Monooxygenase 3 (FMO3) polymorphisms on Itopride exposure. Biopharmaceutics & Drug Disposition. PMID 28255999 DOI: 10.1002/bdd.2074  0.156
2015 Dykstra K, Mehrotra N, Tornøe CW, Kastrissios H, Patel B, Al-Huniti N, Jadhav P, Wang Y, Byon W. Reporting guidelines for population pharmacokinetic analyses. Journal of Pharmacokinetics and Pharmacodynamics. 42: 301-14. PMID 25925797 DOI: 10.1007/S10928-015-9417-1  0.155
2018 Tong X, Xu H, Carlile DJ, Tomkinson H, Al-Huniti N, Zhou D. Population Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung Cancer. Journal of Clinical Pharmacology. PMID 30102413 DOI: 10.1002/jcph.1295  0.149
2020 Nagase M, Shimada H, Nii M, Ueda S, Higashimori M, Ichikawa K, Zhang L, Zhou L, Chen Y, Zhou D, Dunyak J, Al-Huniti N. Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes. Journal of Clinical Pharmacy and Therapeutics. PMID 32227647 DOI: 10.1111/jcpt.13129  0.149
2014 Xu H, Henningsson A, Alverlind S, Tummala R, Toler S, Beaver JS, Al-Huniti N. Population pharmacokinetics of TC-5214, a nicotinic channel modulator, in phase I and II clinical studies. Journal of Clinical Pharmacology. 54: 707-18. PMID 24408516 DOI: 10.1002/jcph.264  0.147
2019 Xu H, Tong X, Mugundu G, Scott ML, Cook C, Arfvidsson C, Pease E, Zhou D, Lyne P, Al-Huniti N. Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch. Journal of Pharmacokinetics and Pharmacodynamics. PMID 30661177 DOI: 10.1007/s10928-019-09619-6  0.145
2015 Bui K, She F, Zhou D, Butler K, Al-Huniti N, Sostek M. The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol. Journal of Clinical Pharmacology. PMID 26248047 DOI: 10.1002/Jcph.613  0.141
2018 Zhou D, Li J, Bui K, Learoyd M, Berges A, Milenkova T, Al-Huniti N, Tomkinson H, Xu H. Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. Clinical Pharmacokinetics. PMID 30357650 DOI: 10.1007/S40262-018-0714-X  0.139
2018 Lu J, Li J, Helmlinger G, Al-Huniti N. Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods. Journal of Pharmacokinetics and Pharmacodynamics. PMID 29556866 DOI: 10.1007/s10928-018-9582-0  0.136
2022 Khaksar Toroghi M, Al-Huniti N, Davis JD, DiCioccio AT, Rippley R, Baum A, Kyratsous CA, Sivapalasingam S, Kantrowitz J, Kamal MA. A Drug-Disease Model for Predicting Survival in an Ebola Outbreak. Clinical and Translational Science. PMID 35895082 DOI: 10.1111/cts.13383  0.134
2022 Nguyen JH, Epling D, Dolphin N, Paccaly A, Conrado D, Davis JD, Al-Huniti N. Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer. Cpt: Pharmacometrics & Systems Pharmacology. PMID 36251220 DOI: 10.1002/psp4.12855  0.131
2021 Khaksar Toroghi M, Bosley J, Powell LM, Zhang Y, Yang F, Pu X, Davis JD, Al-Huniti N. A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglyceride receiving evinacumab. Cpt: Pharmacometrics & Systems Pharmacology. PMID 34327869 DOI: 10.1002/psp4.12694  0.123
2017 Li J, Al-Huniti N, Henningsson A, Tang W, Masson E. Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer. British Journal of Clinical Pharmacology. PMID 28213941 DOI: 10.1111/bcp.13266  0.119
2018 Nayak S, Sander O, Al-Huniti N, de Alwis D, Chain A, Chenel M, Sunkaraneni S, Agrawal S, Gupta N, Visser SAG. Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use. Clinical Pharmacology and Therapeutics. PMID 29330855 DOI: 10.1002/Cpt.978  0.116
2017 Helmlinger G, Al-Huniti N, Aksenov S, Peskov K, Hallow M, Chu L, Boulton D, Eriksson U, Hamrén B, Lambert C, Masson E, Tomkinson H, Stanski D. Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. PMID 28506868 DOI: 10.1016/j.ejps.2017.05.028  0.113
2018 Zhou D, Li J, Learoyd M, Bui K, Berges A, Milenkova T, Al-Huniti N, Tomkinson H, Xu H. Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet formulations in Oncology Patients. Clinical Pharmacology and Therapeutics. PMID 30585620 DOI: 10.1002/Cpt.1338  0.11
2018 Kosinsky Y, Dovedi SJ, Peskov K, Voronova V, Chu L, Tomkinson H, Al-Huniti N, Stanski DR, Helmlinger G. Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model. Journal For Immunotherapy of Cancer. 6: 17. PMID 29486799 DOI: 10.1186/s40425-018-0327-9  0.109
2018 Pike KG, Barlaam B, Cadogan E, Campbell A, Chen Y, Colclough N, Davies NL, DeAlmeida C, Degorce SL, Didelot M, Dishington A, Ducray R, Durant ST, Hassall LA, Holmes JL, ... ... Al-Huniti N, et al. The Identification of Potent, Selective and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one). Journal of Medicinal Chemistry. PMID 29683659 DOI: 10.1021/acs.jmedchem.7b01896  0.109
2007 Al-Shawwa B, Al-Huniti N, Weinberger M, Abu-Hasan M. Clinical and therapeutic variables influencing hospitalisation for bronchiolitis in a community-based paediatric group practice. Primary Care Respiratory Journal : Journal of the General Practice Airways Group. 16: 93-7. PMID 17380234 DOI: 10.3132/Pcrj.2007.00018  0.103
2021 Kamal MA, Kovalenko P, Kosloski MP, Srinivasan K, Zhang Y, Rajadhyaksha M, Lai CH, Kanamaluru V, Xu C, Sun X, Simpson EL, Paller AS, Siegfried EC, Shumel B, Bansal A, ... Al-Huniti N, et al. The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis. Clinical Pharmacology and Therapeutics. PMID 34270797 DOI: 10.1002/cpt.2366  0.103
2019 Nagase M, Ueda S, Higashimori M, Ichikawa K, Dunyak J, Al-Huniti N. Optimal designs for regional bridging studies using the Bayesian power prior method. Pharmaceutical Statistics. 19: 22-30. PMID 31448511 DOI: 10.1002/pst.1967  0.101
2017 Zhou W, Johnson TN, Bui KH, Cheung SYA, Li J, Xu H, Al-Huniti N, Zhou D. Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children. Clinical Pharmacology and Therapeutics. PMID 29027194 DOI: 10.1002/Cpt.905  0.1
2018 Dunyak J, Mitchell P, Hamrén B, Helmlinger G, Matcham J, Stanski D, Al-Huniti N. Integrating dose estimation into a decision-making framework for model-based drug development. Pharmaceutical Statistics. PMID 29322659 DOI: 10.1002/pst.1841  0.1
2009 Krishna R, Garg A, Panebianco D, Cote J, Bergman AJ, Van Hoydonck P, Laethem T, Van Dyck K, Chen J, Chavez-Eng C, Archer L, Lutz R, Hilliard D, Snyder K, Jin B, ... ... Al-Huniti N, et al. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. British Journal of Clinical Pharmacology. 68: 535-45. PMID 19843057 DOI: 10.1111/j.1365-2125.2009.03465.x  0.097
2019 Zhou D, Podoll T, Xu Y, Moorthy G, Vishwanathan K, Ware J, Greg Slatter J, Al-Huniti N. Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and its Active Metabolite, ACP-5862, Using a PBPK Modeling Approach. Cpt: Pharmacometrics & Systems Pharmacology. PMID 31044521 DOI: 10.1002/psp4.12408  0.086
2017 Al-Huniti N, Petersson K, Tang W, Masson E, Li J. Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer. British Journal of Clinical Pharmacology. PMID 29274100 DOI: 10.1111/bcp.13495  0.086
2016 Zhou D, So K, Dymond AW, Vik T, Al-Huniti N, Mariani G, Zorenyi G, Huang Y, Holmes V, Severin P, Rasmussen S, Martin P. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover QT/QTc Study in Healthy Subjects. Clinical Therapeutics. PMID 27837934 DOI: 10.1016/j.clinthera.2016.10.004  0.083
2018 Brilleman SL, Crowther MJ, Moreno-Betancur M, Buros Novik J, Dunyak J, Al-Huniti N, Fox R, Hammerbacher J, Wolfe R. Joint longitudinal and time-to-event models for multilevel hierarchical data. Statistical Methods in Medical Research. 962280218808821. PMID 30378472 DOI: 10.1177/0962280218808821  0.08
2019 Mistry HB, Helmlinger G, Al-Huniti N, Vishwanathan K, Yates J. Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics. Cancer Chemotherapy and Pharmacology. PMID 31020352 DOI: 10.1007/s00280-019-03840-3  0.075
2016 Al-Huniti N. Reply to: Letter to the Editor "Effect of Quinidine, a Strong P-Glycoprotein Inhibitor, on the Pharmacokinetics and Central Nervous System Distribution of Naloxegol". Journal of Clinical Pharmacology. 56: 508. PMID 26954553 DOI: 10.1002/jcph.674  0.075
2019 Zhou L, Higashimori M, Shen K, Zhang Z, Sheng J, Xu H, Horiuchi M, Ichikawa K, Al-Huniti N, Zhou D. Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies. Clinical Pharmacology and Therapeutics. PMID 30802932 DOI: 10.1002/cpt.1352  0.07
2018 Gross AE, Xu H, Zhou D, Al-Huniti N. Simplified aztreonam dosing in patients with end stage renal disease: results of a Monte Carlo simulation. Antimicrobial Agents and Chemotherapy. PMID 30150467 DOI: 10.1128/AAC.01066-18  0.068
2022 Kamal MA, Kuznik A, Qi L, Więcek W, Hussein M, Hassan HE, Patel K, Obadia T, Khaksar Toroghi M, Conrado DJ, Al-Huniti N, Casciano R, O'Brien MP, Barnabas RV, Cohen MS, et al. Assessing the Combined Public Health Impact of Pharmaceutical Interventions on Pandemic Transmission and Mortality: An Example in SARS CoV-2. Clinical Pharmacology and Therapeutics. PMID 35984050 DOI: 10.1002/cpt.2728  0.062
2020 Al-Huniti N, Feng Y, Yu JJ, Lu Z, Nagase M, Zhou D, Sheng J. Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities. Cpt: Pharmacometrics & Systems Pharmacology. PMID 32589767 DOI: 10.1002/psp4.12542  0.062
2020 Nagase M, Aksenov S, Yan H, Dunyak J, Al-Huniti N. Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non-Small Cell Lung Cancer. Cpt: Pharmacometrics & Systems Pharmacology. PMID 31920008 DOI: 10.1002/psp4.12490  0.058
2006 Al-Shawwa B, Al-Huniti N, Titus G, Abu-Hasan M. Hypercholesterolemia is a potential risk factor for asthma. The Journal of Asthma : Official Journal of the Association For the Care of Asthma. 43: 231-3. PMID 16754527 DOI: 10.1080/02770900600567056  0.019
2007 Al-Shawwa BA, Al-Huniti NH, DeMattia L, Gershan W. Asthma and insulin resistance in morbidly obese children and adolescents. The Journal of Asthma : Official Journal of the Association For the Care of Asthma. 44: 469-73. PMID 17654134 DOI: 10.1080/02770900701423597  0.01
Hide low-probability matches.